Member Info for Livedataaccount

Perhaps jaykay just got the wrong number? And there was a bit of confusion at the other end?

Plus the ava6000 trial is maturing now and if you are to believe Avacta's CEO an update on progress could arrive this year. So we are definitely into 'shortly' territory.

It's nice to hear you are okay big hero.

It's just odd the amoint of news flow Avacta were prepared to throw at the market bringing the test to market. A lot of it didn't materialise. Like you say, saliva, cytiva, bbi. There was even an Rns last September I think about tech transfer to Abingdon. And it's pretty much gone to zilch

Does anyone know of Abingdon are actually manufacturing lfts for Avacta yet and they are on sale?

Having the best product doesn't mean it will sell at scale.

Having a talented, well connected, aggressive sales team with a lesser performing test will make more money. There's still a question over manufacturing capacity. Are Abingdon producing Avacta tests? Or will they go the way of bbi and we will find out at the next results it didn't work out.

Thank the Lord Avacta have the AVA600 trial well underway. That will be the share price driver

Greedo, there's no positive in that Rns.

Calamari, I've seen elephants running on wildlife TV shows.

AS mentioned in the presentation they are working with multiple different industries for the lft. Sports etc

Why on earth aren't Avacta releasing this news via Rns. Adding case studies to the website.

Some may not agree that not everything needs an Rns. But with the lft in complete infancy surely they need to get word out there and advertise the fact they working with establishments to supply their lfts!

Who cares. Stick to Avacta

If avacta are selling ~1m LFTs a month as per the slide that says gad are manufacturing around 1m a month the market should have seen that as positive? That's revenue of around 60m gbp at 5 pound per test over 12 months. Not a bad start to build from?

I would have expected the share price to rise on that.

Does the gad manufacturing capacity of ~1m a month mean Avacta actually selling this amount a month? Or gad can manufacture this much if needed?

I only ask as the presentation says Abingdon 'could' add 1-2m a month.

Rather they had written. Current sales made of ~1m a month to be clearer.

That's not to bad at all! And 37pc of that going to apac regions.

Great news. But don't like the timing.

Incredibly arrogant that Ndn assumes every investor is hanging into Myles Mcnulty words. I respect the chap for the effort he puts into his research and good luck to the fella. Seems like a genuine affable guy. Bu does by any means thinks I would follow his investment advice.

The fact the guy changes his name to McNumpty says a lot. Like a young child that feels threatened by the adult. I don't really have a view on Myles Mcnulty myself but Ndn seems like a strange one.

Llamas come from Peru don't they?

Heres a curveball!
Perhaps Avacta could provide an operational update for the diagnostics business?

Worth considering not all that contract money is going to the Chinese. All these tests are bought via resellers, innova backed by us hedge fund etc. So they are taking their cut, a large cut I imagine.

Medco resell the Chinese acon flowfex I believe
All these new awards are for the Chinese.